BC Innovations | Jan 31, 2018
Distillery Therapeutics


INDICATION: Gastric cancer Patient sample, cell culture and mouse studies suggest inhibiting IRF3 could help treat gastric cancer. In patient samples, high levels of IRF3 tumor RNA and protein correlated with tumor size and poor...
BC Week In Review | May 5, 2014
Company News

Galena Biopharma, MD Anderson Cancer Center, U.S. Department of Defense cancer news

The Department of Defense awarded the cancer center an undisclosed grant to fund a Phase II trial with Galena's NeuVax nelipepimut-S to prevent recurrence in breast cancer patients overexpressing epidermal growth factor receptor 2 ( EGFR2...
BC Week In Review | Jan 20, 2014
Company News

Dr. Reddy's, Galena Biopharma deal

Galena granted Dr. Reddy's exclusive rights to develop and commercialize NeuVax nelipepimut-S to treat breast and gastric cancer in India. Dr. Reddy's is responsible for conducting a Phase II trial in gastric cancer, which is...
BC Week In Review | Mar 18, 2013
Clinical News

Nelipepimut-S: Phase IIb started

Galena disclosed in its 2012 earnings that investigators began a single-blind, placebo-controlled Phase IIb trial to compare intradermal NeuVax plus Herceptin trastuzumab given every 3 weeks for 1 year vs. Herceptin plus granulocyte macrophage colony-stimulating...
BC Innovations | Mar 7, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity Inhibitor of k-light polypeptide gene enhancer in B cells kinase-e (IKBKE; IKK-i); TANK-binding kinase 1 (TBK1) Mouse and...
BC Extra | Dec 18, 2012
Financial News

Galena Biopharma planning follow-on

Galena Biopharma Inc. (NASDAQ:GALE) said it is planning a follow-on underwritten by Piper Jaffray. Galena's NeuVax is in the Phase III PRESENT trial to prevent recurrence of early stage, node-positive breast cancer. NeuVax is a...
BC Week In Review | Dec 17, 2012
Company News

Galena Biopharma, Leica Microsystems deal

Leica's histopathology division Leica Biosystems will develop a companion diagnostic using its Bond Oracle HER2 IHC System to aid in selecting breast cancer patients to enroll in the ongoing Phase III PRESENT trial of Galena's...
BC Week In Review | Apr 9, 2012
Clinical News

NeuVax: Phase III started

Galena disclosed in its 4Q11 earnings that in January it began the double-blind, international Phase III PRESENT trial evaluating NeuVax vs. Leukine sargramostim in about 700 patients with operable early-stage, node-positive breast cancer with low...
BC Week In Review | Oct 3, 2011
Company News

Galena Biopharma cancer, dermatology news

RXi Pharmaceuticals Corp. changed its named to Galena Biopharma Inc. and said it will separate its cancer and RNAi assets into two public companies. The first - which will be named Galena - will develop cancer vaccines,...
BC Extra | Sep 27, 2011
Company News

RXi to separate RNAi, cancer assets

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said Monday it will separate its cancer and RNAi assets into two public companies. The first -- named Galena Biopharma Inc. -- will develop cancer vaccines, including NeuVax and a recently...
Items per page:
1 - 10 of 74